Alzheimer's disease Infusion Therapy

Living with Alzheimer's disease presents unique challenges for patients and their families. At Violet Health, we're committed to providing the most advanced treatment options available, including cutting-edge infusion therapies that represent a new frontier in Alzheimer's care. We're proud to offer two groundbreaking FDA-approved medications: Leqembi (lecanemab) and Kisunla (donanemab) – treatments that target the underlying pathology of Alzheimer's disease.

Alzheimer's disease affects millions of Americans, causing progressive memory loss, cognitive decline, and changes in behavior and personality. For decades, treatment options focused primarily on managing symptoms rather than addressing the root causes of the disease. However, recent scientific breakthroughs have led to the development of disease-modifying therapies that target amyloid plaques, which are abnormal protein deposits in the brain that are hallmarks of Alzheimer's disease.

Before beginning infusion therapy, it's crucial to confirm the presence of amyloid pathology in the brain. At Violet Health, we utilize the Precivity AD2 blood test; a simple blood test that measures specific biomarkers associated with Alzheimer's disease pathology. This FDA-cleared test analyzes the ratio of amyloid beta proteins along with other key markers to determine the likelihood of amyloid plaques in the brain. We are among the only locations in Michigan offering this revolutionary testing service.

The Precivity AD2 test is a simple blood test that measures specific biomarkers associated with Alzheimer's disease pathology. This FDA-cleared test analyzes the ratio of amyloid beta proteins (Aβ42/Aβ40) along with other key markers to determine the likelihood of amyloid plaques in the brain.

Key Advantages of Precivity AD2:

Convenience and Accessibility

It is a simple blood draw that can be performed in our office, no special preparation required. It is much more accessible than traditional PET scans or lumbar punctures

High Accuracy

Clinically validated with over 90% accuracy in detecting brain amyloid pathology. Helps reduce the need for more invasive diagnostic procedures. Provides reliable results that guide treatment decisions

Cost-Effective

Significantly less expensive than amyloid PET imaging. Often covered by insurance for appropriate candidates. Eliminates the need for multiple diagnostic procedures in many cases